Anthrax Antibody Resubmitted to US FDA by HGS
A week prior to the closing date Human Genome Sciences (HGS) have fixed for prospective buyers to submit bids, HGS have announced that US regulators are to review raxibacumab again for the treatment’s previously-rejected anthrax medication. The US Food and Drug Administration (FDA) have confirmed the receipt of the resubmission of the Biologics License Application